Akari Therapeutics ADR AKTX

$6.40 -0.40 (-5.88%)

Valuation

Market cap
15,539,000
Revenue TTM
$0
Net income TTM
$-17,300,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.04

Trading

Volume
27,939
Avg volume
55,154
Day's range
$6.35 – $7.05
Shares out
2,285,000
Stochastic %K
10%
Beta
1.46
Analysts
Moderate Buy
Price target
$25.50

Price

Company profile

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer typ...

Show more

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.

Industry
Biotechnology
Sector
Healthcare
Phone
929 274 7510
Website
https://www.akaritx.com
Address
401 East Jackson Street, Suite 3300, Tampa, United States

Latest news

Stocktwits

MTN Nov 14, 6:00 AM
$AKTX in 5 short years the share price has eroded from over $2 k to $ 6. Amazing shareholder returns lol.
0 replies
MTN Nov 14, 5:59 AM
$AKTX just look at the chart here, down 99.9% off ATH. Enough said.
0 replies
BioResearcher Nov 13, 4:06 PM
$AKTX One partnership then we will see $50 Tiny float here.
1 replies
BioResearcher Nov 13, 1:51 PM
$AKTX They are taking steps to prepare for Phase 1 trial. If their drug can reach phase 1, that will attract lots of big pharm attentions. because currently most of the novel ADCs are still in preclincal stage.
0 replies
BioResearcher Nov 13, 1:09 PM
$AKTX Down 12% on 14K shares traded !!! Some one is manipulating this stock to buy it low. Especially during bad market condition. Look at yesterday 's trades, they sold 1 share to push it down because it has very low float:
0 replies
MTN Nov 13, 3:20 AM
$AKTX continued downward trend, 52 week low incoming. This will never see 2023 and 2024 share prices. Management never delivers. I keep this in my portfolio as a reminder that the science means nothing when management is grossly incompetent.
0 replies
focafoca99 Nov 12, 10:36 PM
$AKTX issued its third-quarter 2026 results in a press release attached to the 8-K filing.
1 replies
akaritx Nov 12, 9:16 PM
$AKTX Reports Third Quarter 2026 Financial Results and Highlights Continued Progress Toward Clinical Development of Differentiated ADC Payload Platform https://investor.akaritx.com/news-releases/news-release-details/akari-therapeutics-reports-third-quarter-2026-financial-results
0 replies